The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Consent to participate in a clinical trial.
A clients within an age of 55-74 years.
priority will be given to clients who have smoked at least 30 pack-years.
preference will be given to a former smoker who has not smoked for less than 15 years.
Previous diagnosis of lung cancer.
Progressing malignant tumor on symptomatic treatment.
Advanced dementia
Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.
The Institute of Molecular and Translational Medicine, Czech Republic
Lead sponsor
Cancer Research Foundation CR
Collaborator